Collaboration and value creation in an era of cross-sector convergence

Tuesday, June 26, 2018

Focused on collaboration and value creation in an era of cross-sector convergence this session on imperatives, barriers, enablers and shared experiences, will be led by Rogerio Ribeiro, Senior Vice President, Global Health at GSK* and moderated by C&E CEO, Manny Amadi.

Writing in the Stanford Social Innovation Review nearly 10 years ago, Prof Rosabeth Moss Kanter (now of Harvard Business School) observed that: “Increasingly, innovation blossoms where the sectors converge. At these intersections, the exchanges of ideas and values, shifts in roles and relationships, and integration of private capital with public good generate new and better approaches to creating more sustainable [social, environmental and shareholder] value.”

From climate change & resource scarcity, falling levels of trust in institutions and intense stakeholder scrutiny, to the rise of emerging markets, the SDGs, growth in scale, impact & influence of the private sector and changing roles for government and NGO actors, a range of risk and opportunity-based factors have since intensified convergence between the private, public and civil society sectors.

As convergence has intensified, blurring the boundaries between different actors, so has the concept and practice of collaboration – bi-lateral and multilateral – become more central within and across the different sectors. And if collaboration now represents a central imperative for value creation in an era of cross-sector convergence, some live questions arise, including:
• How is the growing private sector focus on purpose being aligned with the mission orientation that intrinsically drives NGOs?
• How can the terms of engagement between the different sectors evolve to ensure greater value creation for all stakeholders?
• What models of collaboration are emerging to support innovation and impact at scale? And,
• What changes in mind-set and practice are required to fully leverage the full promise of convergence?

These and related questions will be addressed at the session on 26th June.

About the series:
C&E’s Breakfast Dialogue series are free, by invitation, informal discussions held over a light breakfast and involving a dozen or so senior participants from corporate, NGO and public-sector backgrounds. They are highly interactive, informed, co-learning discussions in which participants share their perspectives, experiences and insights - under Chatham House rules.

Contact us at https://www.candeadvisory.com/contact if you or your organisation is interested in attending this or future C&E Breakfast Dialogue events.

*As SVP, Global Health at GSK, Rogerio leads the newly established Global Health Unit, which accelerates development and delivery of medicines, vaccines and health interventions for people in the developing world. He has over 25 years’ experience in the pharmaceutical sector, latterly as head of Emerging Markets, leading the commercial pharmaceutical business for the region which included responsibility for Latin America, Africa, Middle East, CIS and India and Asia Pacific.
Rogerio started at GSK as CFO for the Latin American region where he was actively involved in commercial, research and development, manufacturing and business development projects. He was subsequently appointed to General Manager roles in Argentina and Brazil, before leading the Latin America and Caribbean region as President and Regional Director.